Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria
- 1 June 2001
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 51 (6) , 541-546
- https://doi.org/10.1046/j.1365-2125.2001.01395.x
Abstract
Aims To obtain comprehensive bioavailability data for artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) following their separate oral administration to Vietnamese volunteers and to patients with acute, uncomplicated falciparum malaria. Methods Volunteers were randomized to receive either i.v. ARTS (120 mg) followed by oral ARTS (150 mg) 8 h later (Group 1, n = 10), or i.v. ARTS (120 mg) followed by oral DHA (120 mg) 8 h later. Patients, also received oral ARTS (150 mg; Group 3, n = 8) or DHA (120 mg; Group 2, n = 7), in a randomized cross-over study design. Multiple blood samples were collected after each administration and plasma ARTS and/or DHA concentrations were determined by h.p.l.c. Pharmacokinetic descriptors were obtained from noncompartmental analysis and bioavailability was calculated from AUC data. In the patients, the time to 50% parasite clearance (PCT50) and fever clearance time (FCT) also were measured. Results In Group 1 (volunteers), the mean (95% CI) absolute bioavailability of oral ARTS was 80% (62,98%), while in Group 2 (volunteers), the bioavailability of oral DHA was 45% (34,56%). In the patients (Group 3), the bioavailability of oral DHA relative to oral ARTS was 88% (49,127%). The median PCT50 and FCT were 2.3 and 28 h, respectively. Conclusions The study shows that the absolute bioavailability of DHA was significantly lower than that for ARTS in healthy volunteers. The bioavailability of ARTS in volunteers was consistent with previous studies in patients with uncomplicated falciparum malaria. The dose-normalized Cmax and AUC(0,∞) for DHA were significantly greater in patients with falciparum malaria than in healthy volunteers. The high relative bioavailability of DHA in the patients may have been due to lower first-pass clearance. We conclude that, for the treatment of malaria, DHA is likely to be a suitable oral substitute for ARTS. Based on our mean AUC measurements, it appears that equal doses of DHA and ARTS (mg basis) should give equivalent systemic exposure to bioactive DHA in uncomplicated falciparum malaria.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum MalariaAntimicrobial Agents and Chemotherapy, 2001
- Antimalarial Bioavailability and Disposition of Artesunate in Acute Falciparum MalariaAntimicrobial Agents and Chemotherapy, 2000
- Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin.1999
- A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malariaBritish Journal of Clinical Pharmacology, 1998
- Pharmacokinetics and ex vivo anti-malarial activity of sera following a single oral dose of dihydroartemisinin in healthy Thai males.1997
- The rat biliary metabolites of dihydroartemisinin, an antimalarial endoperoxide.1997
- Selective high-performance liquid chromatographic determination of artesunate and α- and β-dihydroartemisinin in patients with falciparum malariaJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- ArtesunateDrugs, 1995
- Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivativesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Metabolism of antimalarial sesquiterpene lactonesPharmacology & Therapeutics, 1990